profile

Oncology Hero

Itovebi Cuts Breast Cancer Mortality, Candel’s Oncolytic Virus Boosts Prostate Outcomes

Published about 1 month ago • 1 min read

​

​

Roche’s Itovebi Cuts Risk of Death by 33% in HER2-Positive Breast Cancer

Context: HER2-positive breast cancer remains an aggressive subtype despite advances in targeted therapies.

What's New? In updated data presented at ASCO, Roche’s anti-HER2 therapy Itovebi (trastuzumab duocarmazine) reduced the risk of death by 33% in pretreated HER2-positive breast cancer, significantly improving overall survival compared to standard therapies.

Why it Matters? This reinforces Itovebi’s growing role in HER2+ treatment and supports further positioning as a key ADC in Roche’s expanding breast cancer portfolio.

​Read More​

Elahere Demonstrates Superiority Over Chemotherapy in Ovarian Cancer

Context: FRα-targeted therapy Elahere has reshaped treatment options in platinum-resistant ovarian cancer.

What's New? New data confirm Elahere significantly improves overall and progression-free survival compared with standard chemotherapy in FRα-high ovarian cancer, reinforcing its front-runner status among ADCs in gynecologic oncology.

Why it Matters? These results strengthen Elahere’s clinical value and may prompt broader use earlier in the treatment paradigm, potentially setting a new standard of care.

​Read More​

Candel’s Oncolytic Virus Shows Durable Survival in Prostate Cancer

Context: Immunotherapy success has been limited in prostate cancer due to low tumor immunogenicity.

What's New? Candel Therapeutics released final data showing its oncolytic viral immunotherapy CAN-2409 in combination with valacyclovir led to a significant survival advantage and T-cell activation in non-metastatic prostate cancer patients, improving outcomes after radiation therapy.

Why it Matters? These results support CAN-2409’s potential as a novel platform to enhance immune response in historically immunotherapy-resistant tumors like prostate cancer.

​Read More​

GLP-1s and Bariatric Surgery Offer Comparable Reductions in Obesity-Linked Cancer Risk

Context: Obesity is a major modifiable risk factor for multiple cancer types, but comparative cancer-preventive data across interventions remain limited.

What's New? A new study shows that patients taking GLP-1 receptor agonists had similar reductions in obesity-related cancer risk as those undergoing bariatric surgery, suggesting metabolic therapy may offer meaningful cancer prevention benefits.

Why it Matters? These findings highlight the broader oncologic value of GLP-1 drugs and may shift the conversation toward medical management of cancer risk in metabolic disease populations.

​Read More​

​

Oncology Hero

Sharing the latest updates in oncology

Read more from Oncology Hero

Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...

about 1 month ago • 1 min read

Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options. What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024. Why it Matters? These findings position...

about 1 month ago • 1 min read

Genmab’s Endometrial Cancer Candidate Outperforms Expectations in Elahere-Competitive Space Context: The antibody-drug conjugate (ADC) market in gynecologic cancers is heating up, particularly following the success of ImmunoGen’s Elahere in ovarian cancer. What's New? Genmab and Seagen's ADC, currently in Phase 2, showed a 36% response rate in recurrent endometrial cancer, exceeding internal forecasts and prompting an accelerated push into Phase 3 development. Why it Matters? The results...

about 1 month ago • 1 min read